Addex Therapeutics Ltd (SWX:ADXN)

Market Cap	5.25M +0.3%
Revenue (ttm)	173.00K -57.8%
Net Income	-6.73M
EPS	-0.06
Shares Out	116.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,414
Average Volume	225,606
Open	0.0480
Previous Close	0.0450
Day's Range	0.0450 - 0.0480
52-Week Range	0.0336 - 0.0850
Beta	1.98
RSI	52.52
Earnings Date	Apr 27, 2026

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: ADXN